CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Lenalidomide 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01575860
NCT01575860Phase 2Completed
CompareCT.gov

Maintenance Lenalidomide Therapy After Autologous Stem Cell Transplant in Patients With High Risk Relapsed/Refractory Lymphomas

Abramson Cancer Center at Penn Medicine·interventional·Posted Apr 12, 2012·Updated Mar 27, 2023

In Brief

A Phase 2 clinical trial evaluating Lenalidomide for Lymphoma. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This study is being conducted to evaluate the overall safety of lenalidomide (also known as Revlimid) in patients with lymphoma, and to determine whether it is effective in preventing this disease from returning after stem cell transplant. This study will also determine the dose of lenalidomide that can be given without causing severe side effects. Lenalidomide has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of lymphoma. At least 28 people will be enrolled on this study at the University of Pennsylvania.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 12, 2012
Enrollment StartApr 1, 2012
Primary CompletionMay 30, 2018
Study CompletionOct 31, 2022
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 14.2 years ago

Interventions

Lenalidomidedrug

Lenalidomide, 10mg, oral tablets, daily